SPIRENDOLOL

Details

Stereochemistry	RACEMIC
Molecular Formula	C21H31NO3
Molecular Weight	345.4757
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)NCC(O)COC1=C2CC3(CCCCC3)C(=O)C2=CC=C1

InChI

InChIKey=YLBMSIZZTJEEIO-UHFFFAOYSA-N

InChI=1S/C21H31NO3/c1-20(2,3)22-13-15(23)14-25-18-9-7-8-16-17(18)12-21(19(16)24)10-5-4-6-11-21/h7-9,15,22-23H,4-6,10-14H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C21H31NO3
Molecular Weight	345.4757
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6148382 | https://www.ncbi.nlm.nih.gov/pubmed/2861973

Spirendolol (LI 32-468) is a β adrenergic receptor antagonist. It possesses high affinity for metabolic beta-adrenoreceptors which mediate glycogenolysis that is 100 times more potent than propranolol. In human volunteer studies, a single dose of 2 mg LI 32-468 elicited virtually no cardiac beta-adrenoreceptor blockade (predominantly beta-1), whereas a maximal metabolic beta-adrenoreceptor blocking effect (beta-2) was demonstrated. Spirendolol was a potent inhibitor of ocular beta-adrenoceptors, with a 9-12 fold selectivity over inhibition of beta-adrenoceptors in cardiac tissue. When applied topically, Spirendolol was more effective than timolol in decreasing intraocular pressure in normal albino rabbits.

CNS Activity

Approval Year

PubMed

Title	Date	PubMed
Binding potencies of 3 new beta 2 specific blockers to beta receptors in the ciliary processes and the possible relevance of these drugs to intraocular pressure control.	1984 Apr	6142724
Biochemical and physiological effects of S-32-468, a beta-adrenoceptor antagonist with possible oculoselectivity.	1985 Mar	2861973
Platelet activity and selective beta-blockade in migraine prophylaxis.	1988 Jun	2897733

Sample Use Guides

In Vivo Use Guide

In order to study the mode of action of beta-adrenoreceptor antagonists in essential tremor the efficacy of single oral doses of 2, 4 and 10 mg Spirendolol (LI 32-468) was compared with a single oral dose of 120 mg propranolol in a randomised, double blind, placebo controlled trial.

Route of Administration: Oral

In Vitro Use Guide

Spirendolol (LI 32-468) binds potently (KD=6.6 nM) to beta2-receptor sites derived from the ciliary processes of animal eyes.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:35:25 GMT 2023` Edited by `admin` on `Fri Dec 15 15:35:25 GMT 2023`
Record UNII	96789094BR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SPIRENDOLOL

Official Name

English

LI-32-468

Code

English

SPIRO(CYCLOHEXANE-1,2'-(2H)INDEN)-1'(3'H)-ONE, 4'-(3-((1,1-DIMETHYLETHYL)AMINO)-2-HYDROXYPROPOXY)-

Systematic Name

English

S-32-468

Code

English

spirendolol [INN]

Common Name

English

SUBSTANCE-32468

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C29576